Overview

Cetuximab & Concomitant-Boost Accelerated RT in Patients With Locally Advanced Oropharynx Squamous Cell Carcinoma.

Status:
Unknown status

Trial end date:
2009-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the 1-year rate of locoregional disease control in the experimental arm, using a control arm to avoid selection bias.

Phase:

Phase 2

Details

Lead Sponsor:

Trial Form Support S.L.

Collaborators:

Merck KGaA
Merck KGaA, Darmstadt, Germany

Treatments:

Cetuximab